Prostate Cancer | Specialty

Dr. Stein on Commercial Tests to Determine Therapies for Prostate Cancer

January 19th 2017

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses commercial tests for determining therapies for patients with prostate cancer.

Dr. Dreicer Discusses Challenges of Radium-223 in Prostate Cancer

January 18th 2017

Robert Dreicer, MD, associate director for clinical research and deputy director of the University of Virginia Cancer Center, discusses the questions that surround radium-223.

Dr. Tendulkar Discusses Post-Prostatectomy Radiation Therapy

January 17th 2017

Rahul Tendulkar, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses post-prostatectomy radiation therapy and its impact on reducing prostate cancer mortality.

Dr. Buffington Discusses Prostate Cancer Screening

January 13th 2017

Philip J. Buffington, MD, chief medical officer, The Urology Group, discusses effective prostate cancer screening methods and when to use active surveillance.

Dr. Albala on the Benefits of Robotic Surgery in Prostate Cancer

January 12th 2017

David Albala, MD, urologist and medical director, Associated Medical Professionals, discusses the benefits associated with robotic surgery in the treatment of patients with prostate cancer.

Expert Discusses Docetaxel's Continued Significance in Prostate Cancer

January 12th 2017

William Oh, MD, discusses the continued significant of docetaxel in advanced prostate cancer.

Dr. Dreicer on Ongoing Trials in Prostate Cancer

January 11th 2017

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses novel agents or clinical trials in development designed to help guide treatment decisions for patients with prostate cancer.

Challenges Persist in Deploying ADT in Prostate Cancer

January 11th 2017

In 1941, Charles Brenton Huggins, MD, observed that prostate cancer could be controlled by hormone-directed treatments, a discovery for which he was awarded half the Nobel Prize in Physiology or Medicine in 1966.

Dr. Mehlhaff on the Evolution of the Treatment Landscape in Prostate Cancer

January 10th 2017

Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the ways in which the treatment landscape in prostate cancer has evolved in recent years.

Dr. Stein on Trials Investigating Biomarkers in Prostate Cancer

January 9th 2017

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses trials investigating the use of circulating tumor cells as biomarkers for patients with prostate cancer.

Dr. Oh on the Safety Profile of Docetaxel in Prostate Cancer

January 6th 2017

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses the safety profile of docetaxel when administered to patients with prostate cancer.

The Future of Biomarkers in Prostate Cancer

January 6th 2017

At this year’s Chemotherapy Symposium held in New York, a standout presentation by Mark Stein, MD, showed that there is a lot of promise in the area of circulating tumor cell biomarkers for patients with prostate cancer.

Dr. Twardowski on Steps Toward Optimal Sequencing for mCRPC Therapies

December 17th 2016

Przemyslaw W. Twardowski, MD, director, Prostate Oncology Strategic Program, director, Genitourinary Program, clinical professor, Department of Medical Oncology and Therapeutics Research, discusses the necessary steps toward determining optimal sequencing of treatments for patients with metastatic castration-resistant prostate cancer.

Dual Androgen Blockade Ineffective After Enzalutamide in mCRPC

December 16th 2016

Adding enzalutamide to abiraterone acetate failed to improve progression-free survival versus abiraterone alone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer who progressed on enzalutamide.

Expert Explains Evolving Role of Radium-223 in mCRPC

December 13th 2016

For patients with metastatic castration-resistant prostate cancer, the radiopharmaceutical radium-223 dichloride has proven to be an efficacious bone-targeted agent.

Patient-Friendly Policies Extend to Decision Making

December 12th 2016

It was not that long ago that decisions regarding cancer management were essentially made exclusively by the treating physician, with patients simply being informed of “the plan” for their treatment.

Prostate Cancer Screening & Early Detection

December 7th 2016

Genetic Testing and Prostate Cancer

December 7th 2016

Monitoring Patients During Treatment for Advanced Prostate Cancer

December 7th 2016

Age, Exercise, and ADT for Prostate Cancer

December 7th 2016